A Potential New Covid19 Treatment & Concerns About Fetal DNA In Biologicals

Guest: Theresa Deisher, PhD. Dr. Theresa Deisher’s career has focused on discovering and developing new therapies for grievous human illness. Dr. Deisher obtained her Ph.D. in Molecular and Cellular Physiology from Stanford University and has spent over 30 years in commercial biotechnology. Prior to founding AVM Biotechnology and Sound Choice Pharmaceutical Institute (SCPI), she worked with leading biotechnology companies, including Genentech, Repligen, ZymoGenetics, Immunex, and Amgen. AVM Biotechnology does not use morally illicit material in any process and develops products that improve outcomes without additional suffering, because side effects from treatments of cancers or infections should never be worse than the diseases themselves. SCPI’s mission is to end human trafficking in biomedical research. Dr. Deisher is an inventor on 47 issued US/EU/Japan patents and 3 discoveries in clinical trials. She was the first to discover adult cardiac derived stem cells and has been a champion of adult stem cell research. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.